The next‑gen paclitaxel‑eluting drug‑coated balloon with TransferTech nano‑layer coating for optimised drug delivery, fast deflation and excellent handling
Essential Pro is designed for treating stenosis in coronary arteries, bypass grafts, small vessels (<2.5 mm), residual stenosis post-stent, and pre/post-dilation of coronary stents
The TransferTech nanotechnology deposits a uniform, ultrathin layer of 3 µg/mm² paclitaxel and excipient (80/20 ratio), ensuring durable coating, minimal particle loss, and fast, effective drug transfer in 30–60 sec .
It features enhanced pushability via dual distal shafts, fast deflation through enlarged inflation channels, and improved visibility thanks to metallic radiopaque markers and hydrophilic Hydrax Plus coating
| Drug Dose | 3 µg/mm² (Paclitaxel + excipient) |
|---|---|
| Catheter Type | Rapid Exchange (RX), 142 cm |
| Guidewire | 0.014″ compatible |
| Shaft Options | 2.6 F (≤3 mm) / 2.7 F (≥3.25 mm) |
| Pressure Ratings | Nominal: 6 atm | Burst: 16 atm |
| Deflation Time | Fast – enlarged inflation channel |
| Radiopaque Markers | 2 Pt/Ir markers |
In a multi‑center registry of 71 small‑vessel cases (<2.5 mm; 56% diabetic), Essential Pro demonstrated a 4.2% TLF and 9.9% MACE at 12 months
A prospective ISR study showed 94% angiographic success and TLF at 24 months of 13.3%, supporting its role as a safe, effective ISR treatment.
The 2024 Buenos Aires single‑center study (n=160) reported 100% delivery success, 98.5% TIMI 3 flow, low 1‑year TLR (2.5%) and excellent long‑term safety.